Detailed analysis of cytomegalovirus CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease

Cytotherapy

Volumn 10, Issue 3, 2008, Pages 289-302

  Hobeika, A C ^a   Osada, T ^a   Serra, D ^a   Peplinski, S ^a   Hanson, K ^a   Tanaka, Y ^a   Niedzwiecki, D ^a   Chao, N ^a   Rizzieri, D ^a   Lyerly, H K ^a,b   Clay, T ^a   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Cytomegalovirus; Graft versus host disease; Stem cell transplantation; T cells

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; CYTOKINE; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION RISK; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ALLOTRANSPLANTATION; CELL CLONE; CELL PROLIFERATION; CYTOMEGALOVIRUS; DRUG EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KINETICS; LYMPHOCYTE ACTIVATION; NEOPLASM; PATHOLOGY; SECRETION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CLONE CELLS; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KINETICS; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDES; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 42449123139     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240801927040     Document Type: Article

References (31)

1. Asano-Mori, Y., Oshima, K. and Sakata-Yanagimoto, M. (2005) High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant, 36, pp. 813-819.
2. Frere, P., Baron, F. and Bonnet, C. (2006) Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant, 37, pp. 411-418.
3. Hebart, H. and Einsele, H. (2004) Specific infectious complications after stem cell transplant. Support Care Cancer, 12, pp. 80-85.
4. Meyers, JD, Flournoy, N. and Thomas, ED. (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis, 153, pp. 478-488.
5. Goodrich, JM, Bowden, RA and Fisher, L. (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med, 118, pp. 173-178.
6. Salzberger, B., Bowden, RA and Hackman, RC (1997) Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood, 90, pp. 2502-2508.
7. Reusser, P., Riddell, SR, Meyers, JD and Greenberg, PD. (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood, 78, pp. 1373-1380.
8. Avetisyan, G., Larsson, K. and Aschan, J. (2006) Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant, 38, pp. 687-692.
9. Riddell, SR, Watanabe, KS and Goodrich, JM (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science, 257, pp. 238-241.
10. Cobbold, M., Khan, N. and Pourgheysari, B. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med, 202, pp. 379-386.
11. Einsele, H., Roosnek, E. and Rufer, N. (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood, 99, pp. 3916-3922.
12. Micklethwaite, K., Hansen, A. and Foster, A. (2007) Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 13, pp. 707-714.
13. Peggs, KS, Verfuerth, S. and Pizzey, A. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362, pp. 1375-1377.
14. Perruccio, K., Tosti, A. and Burchielli, E. (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood, 106, pp. 4397-4406.
15. Trivedi, D., Williams, RY and O'Reilly, RJ (2005) Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood, 105, pp. 2793-2801.
16. + T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother, 29, pp. 436-443.
17. He, TC, Zhou, S. and da Costa, LT (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA, 95, pp. 2509-2514.
18. Amalfitano, A., Hauser, MA and Hu, H. (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol, 72, pp. 926-933.
19. Lyons, AB. (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods, 243, pp. 147-154.
20. Hobeika, AC, Morse, MA and Osada, T. (2005) Enumerating antigen-specific T-cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother, 28, pp. 63-72.
21. Klebanoff, CA, Gattinoni, L. and Restifo, NP. (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev, 211, pp. 214-224.
22. Walter, EA, Greenberg, PD and Gilbert, MJ (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med, 333, pp. 1038-1044.
23. Dang, Y., Knutson, KL and Goodell, V. (2007) Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res, 13, pp. 1883-1891.
24. Leen, AM, Myers, GD and Sili, U. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med, 12, pp. 1160-1166.
25. Peggs, K., Verfuerth, S. and Pizzey, A. (2002) Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood, 99, pp. 213-223.
26. Micklethwaite, K., Hansen, A. and Foster, A. (2007) Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 13, pp. 707-714.
27. Szmania, S., Galloway, A. and Bruorton, M. (2001) Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood, 98, pp. 505-512.
28. Walter, EA, Philip, D. and Greenberg, MD (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med, 333, pp. 1038-1044.
29. Pira, G Li, Bottone, L. and Ivaldi, F. (2005) Generation of cytomegalovirus (CMV)-specific CD4 T cell lines devoid of alloreactivity, by using a mixture of CMVphosphoprotein65 peptides for reconstitution of the T helper repertoire. J Infect Dis, 191, pp. 215-226.
30. Lonial, S., Hicks, M. and Rosenthal, H. (2004) A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant, 10, pp. 848-857.
31. Lee, PP, Yee, C. and Savage, PA (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med, 5, pp. 677-685.